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carcinoma and therapeutic potentials of
virus-mediated CHD1L depletion
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Jun Huang,2 Xin-Yuan Guan1,3,4
ABSTRACT
Background Hepatocellular carcinoma (HCC) is among
the most lethal of human malignancies. It is difficult to
detect early, has a high recurrence rate and is refractory
to chemotherapies. Amplification of 1q21 is one of the
most frequent genetic alterations in HCC. CHD1L is
a newly identified oncogene responsible for 1q21
amplification. This study aims to investigate the role of
CHD1L in predicting prognosis and chemotherapy
response of patients with HCC, its chemoresistant
mechanism and whether virus-mediated CHD1L silencing
has therapeutic potentials for HCC treatment.
Methods The clinical significance of CHD1L in a cohort
of 109 HCC cases including 50 cases who received
transarterial chemoembolisation treatment was
assessed by clinical correlation and KaplaneMeier
analyses. A CHD1L-overexpressing cell model was
generated and the mechanism of chemoresistance
involving CHD1L was investigated. An adenovirus-
mediated silencing method was used to knockdown
CHD1L, and its effects on tumorigenicity and
chemoresistance were investigated in vivo and in vitro.
Results Overexpression of CHD1L was significantly
associated with tumour microsatellite formation
(p¼0.045), advanced tumour stage (p¼0.018), overall
survival time (p¼0.002), overall survival time of patients
who received transarterial chemoembolisation treatment
(p¼0.028) and chemoresistance (p¼0.020) in HCC.
Interestingly, CHD1L could inhibit apoptosis induced by
5-fluorourail (5-FU) but not doxorubicin. The mechanistic
study revealed that the involvement of the Nur77-
mediated pathway in chemotherapeutic agent-induced
apoptosis can dictate if CHD1L could confer resistance to
chemotherapy. Furthermore, an adenoviral vector
containing short hairpin RNAs against CHD1L
(CHD1L-shRNAs) could suppress cell growth,
clonogenicity and chemoresistance to 5-FU. An in vivo
study found that CHD1L-shRNAs could inhibit xenograft
tumour growth and increase the sensitivity of tumour
cells to 5-FU in nude mice.
Conclusions This study highlighted for the first time the
prognostic value of CHD1L in HCC and the potential
application of virus-mediated CHD1L silencing in HCC
treatment.
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most
common causes of cancer morbidity and mortality
in Southeast Asia, China and the USA, where its
incidence has increased by >90% over the past
three decades.1 2 Curative surgery offers the hope
for long-term survival to patients suffering from
HCC; however, patients are commonly diagnosed
at the advanced stage and this means that liver
resection is only suitable for a minority of patients.
For the majority of patients, the median survival is
w6 months.3 Chemotherapy is one of the mainstay
treatments for patients with inoperable disease.
HCC is a chemoresistant cancer, and the efficacy of
chemotherapeutic drugs is generally believed to
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Significance of this study
What is already known about this subject?
< Amplification of 1q21 is detected in 58e78% of
human HCCs, and a target oncogene CHD1L
responsible for this amplification event has been
identified.
< CHD1L inhibits cell apoptosis by blocking the
Nur77-mediated apoptotic pathway.
< The clinical significance of CHD1L and the
therapeutic potentials of CHD1L are still
unknown.
What are the new findings?
< CHD1L overexpression in HCC correlates with
the unfavourable clinical features, chemotherapy
responsiveness and survival of patients with
HCC.
< CHD1L inhibits chemotherapeutic agent-induced
apoptosis via the Nur77/cytochrome c/caspase
9 pathway, providing a novel insight into the
underlying mechanism of chemoresistance in
HCC.
< The involvement of the Nur77-mediated
pathway in drug-induced apoptosis can
dictate if CHD1L could confer resistance to
chemotherapy.
< Virus-mediated CHD1L depletion can abolish the
malignant phenotypes of tumour cells and
increase chemosensitivity to chemotherapeutic
agent.
How might it impact on clinical practice in the
foreseeable future?
< CHD1L expression can be used to predict
prognosis and chemotherapeutic response of
patients with HCC.
< Virus-mediated CHD1L silencing might serve as
promising novel therapeutic options for patients
with HCC.
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depend on their ability to trigger apoptosis.4 5 Actually, HCC is
one of the well identified cancers that are most resistant to
systemic chemotherapy, with the reported response rate varying
from 0% to 20% and a median survival of only 4 months.6
The overall poor outcome thus underlines the urgent need
for reliable biomarkers in the diagnosis and prognosis of HCC
and improved molecular targets for the development of more
efficient treatments.
It is believed that HCC, like many other solid tumours,
develops from the accumulation of alterations of cancer-related
genes critical to processes such as cell proliferation, apoptosis
and other functions. Amplification of chromosome 1q is the
most frequent genetic alteration in HCC, which was detected in
58e78% of primary HCC cases by comparative genomic
hybridisation.7e9 The minimal amplified region has been
narrowed down to 1q21, and a novel oncogene, CHD1L (also
named ALC1), has been identified.10 The oncogenic function of
CHD1L in HCC development and progression has been
demonstrated by both in vitro and in vivo studies.10e13 In the
present study, the association between the CHD1L over-
expression and clinicopathological features in HCC was inves-
tigated. As described previously, CHD1L is able to bind to Nur77
and inhibits the latter ’s nuclear to mitochondrial translocation,
and the subsequent Nur77-mediated caspase activation and
apoptosis, thereby strongly extending HCC cell survival by
inhibiting Nur77-mediated apoptosis.12 In light of this, the
effect of CHD1L on chemotherapy and the mechanism under-
lying the chemoresistance of HCC were also investigated. More
interestingly, the viral delivery of small interfering RNA (siRNA)
targeting CHD1L as cancer therapeutics was further investigated
and is discussed in this study.
MATERIALS AND METHODS
Patients and clinical specimens
Between June 2001 and June 2008, a retrospective cohort of 109
patients with HCC who underwent hepatectomy at Sun Yat-
Sen University Cancer Center (Guangzhou, China) were
enrolled into this study. All patients were diagnosed with
primary HCC, and none had received prior radio- or chemo-
therapy before surgery. Of the 109 patients, 59 have developed
recurrent HCCs within 4 years. Fifty patients had prechemo-
therapy biopsies and then received about three cycles of trans-
arterial chemoembolisation (TACE) treatment (figure 1). The
studies using human tissue were reviewed and approved by the
Committees for Ethical Review of Research involving Human
Subjects at University of Hong Kong and Cancer Center of Sun
Yat-Sen University, China.
TACE treatment
Cisplatin (CDDP), 5-fluorourail (5-FU) and an emulsion
consisting of doxorubicin (DOX) and lipiodol were injected in
turn into the arteries that fed the tumours. The median dose of
lipiodol was 10 mg (5e20 mg). The doses of the chemotherapy
agents were: DOX 60 mg/m2, CDDP 120 mg/m2 and 5-FU
600 mg/m2 every month for up to three cycles.
Definition of an objective response
The effects of TACE on the tumour were assessed by dynamic CT
within the first month after TACE treatment. The tumour
response was evaluated using the Response Evaluation Criteria in
Solid Tumors criteria.14 Patients were categorised into two
groups. Thosewhom did not obtain clinical benefit and developed
progressive disease were classified as the ‘chemotherapy-resistant’
group. Those who obtained clinical benefit by achieving complete
response, partial response and stable disease were classified as the
‘chemotherapy-sensitive’ group.
Immunohistochemistry (IHC)
IHC was performed as described previously.13 CHD1L immu-
noreactivity was scored as absent expression (0), weak expres-
sion (1), moderate expression (2) and strong expression (3)
according to the semi-quantitative scoring method as reported
by Ng et al.15 In this study, compared with non-tumour tissue,
the higher IHC score of CHD1L in the tumour was defined as
‘overexpression of CHD1L in HCC’. For prechemotherapy
biopsies, a low (0e1) or high (2e3) IHC score of CHD1L in
tumour tissue was defined as ‘CHD1L-negative’ or ‘CHD1L-
positive’ HCC, respectively. In this study, all histological eval-
uations were carried out in a double-blind manner by two
pathologists to minimise observational bias.
Cell lines
HCC cell lines QGY-7703 and PLC8024 were obtained from the
Institute of Virology, Chinese Academy of Medical Sciences,
Beijing, China. The cells were maintained in Dulbecco’s modi-
fied Eagle’s medium (DMEM; Gibco BRL, Grand Island, New
York, USA) supplemented with 10% fetal bovine serum (FBS)
(Gibco BRL). The cells were incubated at 378C in a humidified
chamber containing 5% CO2.
XTT proliferation assay
Chemotherapy-induced cytotoxicity was determined by XTT
Cell Proliferation Assay (Roche Diagnostics, Indianapolis,
Indiana, USA) according to the manufacturer ’s instructions. The
relative number of viable cells as compared with the number of
cells without drug treatment was expressed as percentage cell
viability using the following formula: cell viability (%)¼A490 of
treated cells/A490 of untreated cells. Three independent experi-
ments were performed in duplicate.
Confocal microscopy
For visualising Nur77 protein, cells were transiently transfected
with a green fluorescent protein (GFP)/Nur77 expression
Figure 1 Study flow chart: inclusion criteria, exclusion criteria and
outcome. HCC, hepatocellular carcinoma.
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construct as described previously.12 For mitochondrial staining,
before the fixation, Mitotracker Red (Molecular Probes, Eugene,
Oregon, USA; 100 nM) was added to the culture medium
and stained cells at 378C for 15 min. Slides were fixed and
mounted with Vectashield Mounting Medium containing
4’,6-diamidino-2-phenylindole (DAPI; Vector Laboratories,
Burlingame, California, USA), and images were captured using
a Zeiss LSM 510 Meta confocal laser-scanning microscope (Carl
Zeiss MicroImaging, Thornwood, New York, USA).
TUNEL assay
Apoptotic cells were determined by the terminal deoxy-
ribonucleotidyl transferase (TDT)-mediated dUTP-digoxigenin
nick end labelling (TUNEL) assay. Apoptotic cells were deter-
mined using the In Situ Cell Death Detection Kit POD (Roche
Diagnostics), which quantitatively determines DNA fragmen-
tation visualised with a fluorescence microscope. Apoptotic
indices were obtained by counting the percentage of TUNEL-
positive cells (green colour).
In vitro tumorigenic assays
For foci formation assay, 13103 cells were seeded in a 6-well
plate. After culture for 7 days, surviving colonies (>50 cells/
colony) were stained by Giemsa (Invitrogen, Carlsbad, California,
USA) and counted. Anchorage-independent growth was assessed
by colony formation ability in soft agar. Briefly, 13104 cells were
suspended in 1 ml of soft agar mixture (23DMEM, 20% FBS and
0.7% agarose) and were subsequently overlaid on the agar base.
After 2e3 weeks, colonies ($10 cells) were counted under the
microscope in 10 fields per well. Three independent experiments
were performed in duplicate.
Antibodies and western blotting
Mouse anti-CHD1L and b-actin antibodies were purchased
from Abcam (Cambridge, MA, USA). Rabbit anticaspase 3,
anticaspase 9 and anti-PARP (poly(ADP-ribose) polymerase) and
mouse anticaspase 8 were all purchased from Cell Signaling
Technology (Danvers, Massachusetts, USA). Mouse anti-
cytochrome c (Cyto c) antibody was purchased from Santa Cruz
Figure 2 Overexpression of CHD1L
was associated with a poor survival rate
in hepatocellular carcinoma (HCC).
(A) Representative images of CHD1L
expression in a pair of HCC (right) and
adjacent non-tumour liver tissue (left)
detected by immunohistochemistry
(IHC). Nuclear staining of CHD1L
(brown) was detected in tumour tissue.
The tissue sections were also stained
with H&E as a reference. Original
magnification, 3200. (B) Representative
images of H&E staining (upper left) and
IHC staining with an anti-CHD1L
antibody (lower left) on serial sections
of cirrhotic (Cir) tissue surrounding
a HCC (Tu). The boxed regions are
magnified and shown in the right panels.
(C) H&E staining (left) and IHC analysis
of CHD1L (middle) were performed on
serial sections of cirrhotic (Cir) tissue
surrounding a HCC (Tu). The boxed
regions are magnified and shown in the
right panel. CHD1L was expressed in the
cytoplasm of hepatocytes in cirrhotic
tissue. (D) KaplaneMeier overall
survival (OS) curve of patients with HCC
in correlation with CHD1L expression.
The OS rate was significantly decreased
in patients with HCC with CHD1L
overexpression (+) compared with
patients without CHD1L overexpression
(e) (p¼0.001). (E) KaplaneMeier
analysis indicated that the OS rate of
patients with HCC who received
transarterial chemoembolisation (TACE)
was significantly decreased in the
CHD1L (+) group compared with the
CHD1L(e) group (p¼0.028).
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Biotechnology (Santa Cruz, California, USA). Western blotting
was performed as described previously.10
Construction and amplification of recombinant adenovirus
vectors
Replication-incompetent adenoviruses expressing short hairpin
RNA (shRNA) were constructed using the BLOCK-iTAdenoviral
RNAi Expression System (Invitrogen) according to the manu-
facturer ’s instructions. We first designed four pairs of siRNAs
based on full-length CHD1L (accession no NM_004284). The
sequences that could effectively knock down CHD1L were
converted to shRNA sequences by adding hairpin sequences. The
isolated adenoviral expression cloneswere then digested to expose
the inverted terminal repeat and then transfected into 293A cells
(provided with the kit) using Lipofectamine 2000 (Invitrogen) to
generate crude adenoviral stocks. Large-scale amplification
of adenoviral vectors was conducted in 293A cells and the titres
of the purified virus were determined by standard plaque-forming
assay according to the manufacturer ’s instructions.
Adenoviral infection in vitro
PLC8024 cells were grown to w80% confluency. After washing
with phosphate-buffered saline (PBS), cells were incubated with
adenoviral vectors for 2 h in DMEM containing 5% FBS,
followed by culturing in complete medium.
Xenograft tumorigenesis and treatment with 5-FU in nude mice
PLC8024 cells were used to generate tumours in nude mouse
as described previously.13 When tumours reached w5 mm in
diameter, each mouse was then given an intratumoral injection
of adenoviral vectors (CHD1L-shRNA or Adv-Lacz) at a dose of
23109 plaque-forming units (pfu) in 20 ml of PBS once per week.
After the injection of viral vectors, the mice were treated with
5-FU (40 mg/kg body weight; intraperitoneally) or with 20 ml of
PBS (pH 7.4; intraperitoneally). Tumour growth was assessed by
the average volume of tumours as described previously.13
Statistical analysis
The Statistical Package for the Social Sciences, version 16 (SPSS
16.0, SPSS, Chicago, Illinois, USA) was used for data analysis.
CHD1L expression levels in tumour tissue and matched non-
tumour tissue were compared using Wilcoxon signed rank test.
The clinicopathological features in CHD1L-positive patients and
CHD1L-negative patients were compared using the Pearson c2
test for categorical variables, and an independent Student t test
for continuous data. KaplaneMeier plots and log rank tests were
used for survival analysis. A p value <0.05 was considered
statistically significant.
RESULTS
Patient characteristics
Of the 109 patients (supplementary table 1), 87.1% were male;
the median age was 46 years (range 21e75 years). Most patients
were chronic carriers of hepatitis B virus (89.9%). The median
a-fetoprotein value was 71.34 ng/ml (range 0e210 000 ng/ml). A
total of 102 patients with follow-up data were eligible for overall
survival (OS) analysis (seven patients without follow-up data
were excluded). The median follow-up time was 24.8 months
(95% CI 17.969 to 31.631). Within 4 years (1.0e45.0 months),
59 patients had developed recurrent HCCs and 50 patients had
received about three cycles of TACE treatment (figure 1). These
50 patients were eligible for analyses of OS and the association
between CHD1L expression and chemotherapy outcome.
Overexpression of CHD1L is associated with microsatellite
tumour formation, advanced stage and poor prognosis in HCC
To determine the prevalence and clinical significance of CHD1L
in HCC, the correlation between CHD1L overexpression and the
clinicopathological features was investigated in a retrospective
cohort of 109 HCC cases by IHC. In the 109 cases examined,
CHD1L overexpression was detected in 50.5% (55/109) of HCC
tissues (figure 2A and supplementary table 2). Expression of
CHD1L was significantly stronger in tumour tissues than adja-
cent non-tumour tissues (p<0.001; Wilcoxon signed rank test).
Furthermore, liver cirrhosis was obviously observed at the peri-
tumoral area in 56.9% (62/109) of HCC specimens. In the
Table 1 Clinicopathological correlation of CHD1L expression in HCC
Clinicopathological
features
Number
(n[109)
CHD1L expression
p ValueWithout OE With OE
Gender
Male 95 46 49
Female 14 8 6 0.580
Age
#60 88 46 42
>60 21 8 13 0.332
HbsAg
Negative 12 7 5
Positive 97 47 50 0.556
Serum AFP (ng/ml)
#400 55 29 26
>400 54 25 29 0.567
Tumour size (cm)*
#5 23 15 8
>5 86 39 47 0.103
Cirrhosisy
Absent 29 13 16
Present 70 38 32 0.508
Tumour encapsulationy
Absent 41 21 20
Present 58 30 28 1.000
Microsatellite formationy
Absent 68 40 28
Present 29 10 19 0.045
Tumour stage (AJCC)
Stage I 24 18 6
Stage II 63 27 36
Stage III 22 9 13 0.018
*Tumour size was measured by the length of the largest tumour nodule.
yPartial data are not available, and statistics were based on the available data.
AFP, a-fetoprotein; AJCC, American Joint Committee on Cancer; HBsAg; hepatitis C
surface antigen; HCC, hepatocellular carcinoma; OE, overexpression.
Table 2 The association between CHD1L overexpression and tumour
response to chemotherapy in 50 patients with HCC
Parameters
Number
(N[50)
CHD1L negative
(N[24) (%)
CHD1L positive
(N[26) (%) p Value
Response*
Complete response 0 0 0
Partial response (PR) 11 8 3
Stable disease (SD) 9 6 3
Progressive disease (PD) 30 10 20 0.020
2-year survival ratey 9/24 (37.5%) 2/26 (7.7%)
3-year survival ratey 7/24 (29.2%) 1/26 (3.9%)
Median OS (months)y 21.9 (1.0e44.1) 11.9 (5.4e18.4) 0.028
*The tumour response was evaluated using the Response Evaluation Criteria in Solid
Tumors (RECIST) described in the Materials and methods section.
yOverall survival (OS), 2-year and 3-year survival rate were calculated from the data of the
first treatment, using the KaplaneMeier method.
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peritumoral cirrhotic tissues, absent, weak or moderate expres-
sion of CHD1L was observed in 37.1% (23/62), 43.5% (27/62) or
19.4% (12/62) of HCC cases, respectively (figure 2B and
supplementary table 3). Expression of CHD1L was significantly
higher in tumour tissues than in the corresponding peritumoral
cirrhotic tissues (p<0.001; Wilcoxon signed rank test). Inter-
estingly, CHD1L was expressed in the cytoplasm of hepatocytes
in cirrhotic tissues (figure 2C). The correlation analysis (Peason
c2 test) showed that CHD1L overexpression in HCC tumours
was significantly associated with tumour microsatellite tumour
formation (p¼0.045) and advanced tumour stage (p¼0.018,
table 1). The prognostic significance of CHD1L overexpression
was also studied in this cohort of 102 patients with valid
follow-up data. The results showed that CHD1L overexpression
was significantly associated with poorer OS of patients (log
rank¼11.160, p¼0.001; figure 2B). The 5-year survival rate
dropped from 31.4% (16/51) in patients without CHD1L ovex-
pression (defined as ‘CHD1L negative’) to 7.8% (4/51) in
patients with CHD1L overexpression (defined as ‘CHD1L posi-
tive’). The median OS times in CHD1L-negative (n¼51) and
CHD1L-positive (n¼51) subgroups of HCC patients were
42.6 months (95% CI 35.1 to 50.1) and 19.8 months (95% CI
12.6 to 27.0), respectively. These data indicated that CHD1L
could be a potential prognostic marker to predict the OS of
patients with HCC.
Overexpression of CHD1L correlates with the poorer
outcome of chemotherapy
The effect of CHD1L overexpression on chemotherapy was
further studied in 50 patients with recurrent HCC in this
cohort. They had received TACE treatment with the chemo-
therapeutic drugs 5-FU in combination with DOX and CDDP.
Tumour response to chemotherapy and OS time were calculated
from the date of the first treatment. Among these patients with
HCC, 30/50 (60%) of them developed progressive disease during
chemotherapy and were classified as the ‘chemoresistant’ group.
In the remaining 20 patients, partial response and stable diseases
were observed in 11 and 9 cases, respectively, and they were
defined as the ‘chemosensitive’ group (table 2). IHC results
showed that the frequency of CHD1L overexpression was
significantly higher in the ‘chemoresistant’ group (20/30, 66.7%)
than that in the ‘chemosensitive’ group (6/20, 30%, p¼0.02,
Pearson c2 test, table 2). As shown in figure 2C, overexpression
of CHD1L was also significantly correlated with OS time of
patients with HCC who received chemotherapy (log
rank¼4.835, p¼0.028). The 2-year and 3-year survival rate
dropped from 37.5% and 29.2% in patients with CHD1L-nega-
tive HCC to 7.7% and 3.9% in those with CHD1L-positive
HCC, respectively (table 2). In addition, the median OS time in
CHD1L-negative (n¼24) and CHD1L-positive (n¼26) subgroups
of patients with HCC were 21.9 months (95% CI 1.0 to 44.1)
Figure 3 The inhibitory effect of
CHD1L on 5-fluorouracil (5-FU)-induced
apoptosis. (A) The expression of CHD1L
was detected by western blot analysis
in CHD1L-transfected (CHD1L-C3 and
CHD1L-C6), parental (QGY-7703) and
empty vector-transfected cells (Vec-
7703). (B, C) Cell viabilities of CHD1L-
C3, CHD1L-C6 and Vec-7703 cells were
detected by XTT proliferation assay after
treatment with 5-FU (B) or doxorubicin
(DOX) (C) at the indicated
concentrations for 48 h. Data represent
the mean6SD derived from three
independent experiments with triplicate
wells (*p<0.05; **p<0.01). (D) After
treatment with 5-FU (25 mg/ml) or DOX
(400 ng/ml) for 48 h, the apoptotic index
was determined by TUNEL
(deoxyribonucleotidyl transferase
(TDT)-mediated dUTP-digoxigenin nick
end labelling) assay. The upper panel
shows the representative images of the
TUNEL assay. The apoptotic cells were
stained with fluorescein isothiocyanate
(FITC)-labelled DNA strand breaks
(green signals). The nuclei were
counterstained by 4’,6-diamidino-2-
phenylindole (DAPI). The apoptotic index
was calculated and is summarised in
the bar chart (lower panel). Data
represent the mean6SD derived from
three independent experiments in
triplicate (*p<0.01; **p<0.001).
(E) After treatment with 5-FU or DOX for
the indicated times, the cleavages of
caspase 3 and PARP (poly(ADP-ribose)
polymerase) was detected in CHD1L-C3
and Vec-7703 cells by western blot analysis.
b-Actin was used as a loading control.
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and 11.9 (5.4e18.4) months (95% CI 9.2 to 30.4), respectively
(table 2).
CHD1L inhibits cell apoptosis in HCC cells induced by
5-FU, but not DOX
Since overexpression of CHD1L was significantly associated
with the poor outcomes of chemotherapy in patients with
HCC, we further investigated the inhibitory effect of CHD1L on
two conventional chemotherapeutic agents, 5-FU and DOX. For
this purpose, CHD1L expression plasmid or empty vector was
stably transfected into a HCC cell line QGY-7703 as described
previously.12 Elevated expression of CHD1L was confirmed in
two CHD1L transfectants (CHD1L-C3 and CHD1L-C6) by
western blot analysis (figure 3A). CHD1L-7703- and empty
vector-transfected (Vec-7703) cells were then exposed for 72 h to
varying concentrations of DOX (0, 100, 200, 400, 500 and
600 ng/ml; IC50 at 400 ng/ml) and 5-FU (0, 12.5, 25, 50, 100 and
200 mg/ml; IC50 at 25 mg/ml). The XTT proliferation assay
showed that CHD1L-7703 (C3 and C6) cells were more viable
compared with Vec-7703 cells after 5-FU treatment (figure 3B).
However, no obvious difference in cell viability was observed
between CHD1L-7703 and Vec-7703 cells when cells were
treated with DOX (figure 3C).
Next, we studied whether the preferential survival of CHD1L
transfectants after exposure to 5-FU was attributed to low rates
of apoptosis. After the treatment with 5-FU, the apoptotic cells
were detected by TUNEL assay. The apoptotic index, obtained
by counting the percentage of TUNEL-positive cells, was
compared between CHD1L-7703 and Vec-7703 cells. The
apoptotic index of Vec-7703 cells increased rapidly after the
treatment with 5-FU, reaching >57% after 48 h of exposure to
5-FU (figure 3D). In contrast, the apoptotic index of CHD1L-
7703 cells was significantly lower at every time point in the
presence of 5-FU. However, after DOX treatment, there was no
dramatic difference in the apoptotic index between CHD1L-7703
and Vec-7703 cells (figure 3D). To confirm this finding, activation
of caspase 3 and PARP, which are two typical characteristics of
cell apoptosis, was investigated by western blot analysis in
Vec-7703 and CHD1L-C3 cells. As seen in figure 3E, the cleaved
caspase 3 and PARP were dramatically decreased in CHD1L-C3
cells compared with Vec-7703 cells after 5-FU treatment.
However, no notable difference was detected between CHD1L-
C3 and Vec-7703 cells when cells were treated with DOX. These
data suggest that CHD1L could inhibit the apoptotic progression
of HCC cells upon 5-FU stimulation, but not DOX stimulation.
CHD1L confers chemoresistance by inhibiting the
Nur77/Cyto c/caspase 9 pathway
Our previous study demonstrated that CHD1L is able to block
nuclear to mitochondrial translocation of Nur77 via their
interaction, and subsequently to inhibit Cyto c release into the
cytoplasm and the following activation of caspase 9 and caspase
3, finally inhibiting apoptosis.12 Based on these findings, we
investigated whether the inhibitory effect of CHD1L on 5-FU is
Figure 4 CHD1L inhibits Nur77-mediated apoptosis induced by 5-fluorouracil (5-FU), but not by doxorubicin (DOX). (A and B) After treatment with
DOX (400 ng/ml) (A) or 5-FU (25 mg/ml) (B) for 24 h, GFP/Nur77 (green), mitochondria (red) and nuclei (blue) were captured using confocal
microscopy. Both Vec-7703 and CHD1L-C3 cells showed an exclusively nuclear localisation of Nur77 after treatment with DOX. However, after
treatment with 5-FU, Nur77 in Vec-7703 cells, but not in CHD1L-C3 cells, began to migrate from the nucleus to the mitochondria (bar¼10 mm).
(C and D) The level of cytochrome c (Cyto c) in the cytosolic fraction (C), and expression of caspase 9 and 8 (D) in Vec-7703 and CHD1L-C3 cells were
detected by western blotting after 5-FU or DOX treatment at the indicated time points. b-Actin was used as a loading control. DAPI,
4’,6-diamidino-2-phenylindole.
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associated with the Nur77/Cyto c/caspase 9 pathway. For this
purpose, the GFP/Nur77 expression plasmid was transiently
transfected into Vec-7703 and CHD1L-C3 cells, which were then
treated with 5-FU or DOX. The subcellular location of Nur77
was detected by confocal microscopy. When treated with DOX
for 24 h, apoptosis (characterised as nuclear condensation and
fragmentation) occurred in Vec-7703 and CHD1L-7703 cells
transfected with GFP/Nur77 (figure 4A). In both Vec-7703 and
CHD1L-C3 cells, GFP/Nur77 was exclusively localised in the
nucleus after DOX treatment, suggesting that apoptosis induced
by DOX was not through the Nur77-mediated apoptotic
pathway. However, the nuclear to mitochondrial translocation
of Nur77 was observed in Vec-7703 cells after 5-FU treatment
(figure 4B), suggesting that the proapoptotic effect of 5-FU was
via the Nur77-mediated apoptotic pathway. As expected,
CHD1L could inhibit nuclear to mitochondrial translocation of
Nur77 and the translocation was not observed in CHD1L-C3
cells after 5-FU treatment (figure 4B). The effects of CHD1L on
Cyto c release into the cytoplasm and the activation of caspase 9
were then studied by western blot analysis. Compared with
Vec-7703 cells, the levels of Cyto c in the cytoplasm and of
cleaved caspase 9 were obviously decreased in CHD1L-C3 cells
after 5-FU treatment (figure 4C,D). However, CHD1L had
no effect on Cyto c release and the activation of caspase 9
Figure 5 Adenoviral CHD1L-shRNAs
(short hairpin RNAs) inhibits
tumorigencity and chemoresistance in
vitro. (A and B) Knockdown efficiency of
CHD1L-shRNAs (CHD1L-shRNA1 and
CHD1L-shRNA2) was detected by
quantitiative PCR (A) or western blot
analysis (B) in PLC8024 cells. Cells were
infected with CHD1L-shRNAs at the
indicated concentrations or with the
negative control (Adv-Lacz). For
quantitative PCR, three independent
experiments were performed in
triplicate. b-Actin was used as a loading
control for western blot analysis.
(C) Representative images of the
inhibitory effect of CHD1L-shRNAs on
foci formation in PLC8024 cells
(left panel) compared with parental cells
and Adv-Lacz-infected cells. Surviving
colonies (>50 cells/colony) were
counted and are shown in a bar chart
(right panel). Data represent the
mean6SD derived from three
independent experiments with triplicate
wells (*p<0.01; **p<0.001).
(D) Representative images of colony
formation in soft agar (left panel). The
numbers of colonies ($10 cells) were
counted and are summarised in a bar
chart (right panel). Data represent the
mean6SD derived from three
independent experiments with triplicate
wells (**p<0.001). (E) Effects of
CHD1L-shRNAs on the growth rate in
PLC8024 cells. Growth curves of cells
infected by adenoviral vectors (at
a multiplicity of infection (MOI) of 2)
were detected for 6 days by XTT
proliferation assay. Data represent the
mean6SD derived from three individual
experiments with triplicate wells
(*p<0.001). (F) The inhibitory effect of
CHD1L-shRNAs on chemoresistance to
5-fluorouracil (5-FU). After CHD1L-
shRNA (MOI¼10) infection, PLC8024
cells were treated with 5-FU for 48 h at
the indicated concentration. The cell
viabilities were detected by XTT assay.
Compared with Adv-Lacz, CHD1L-
shRNAs could significantly inhibit the
chemoresistance to 5-FU (*p<0.05;
**p<0.01). Three independent
experiments were performed in
triplicate.
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when Vec-7703 and CHD1L-7703 cells were treated with DOX
(figure 4C,D). Western blot analysis of 5-FU- or DOX-induced
caspase 8 activation indicated that the antiapoptotic effect of
CHD1L on 5-FU or DOX treatment was not associated with the
death signalling pathway. All these data suggested that CHD1L
could inhibit apoptosis induced by 5-FU, rather than DOX, via
the inhibition of the Nur77-mediated apoptotic pathway and
confer chemoresistance to 5-FU.
Virus-mediated CHD1L silencing suppresses the tumorigenic
ability of CHD1L and chemoresistance to 5-FU
To study further the tumorigenic and chemoresistant effects of
CHD1L in HCC, two shRNAs against CHD1L were cloned into
the pENTR/U6 vector for adenovirus vector construction
(CHD1L-shRNA1 and CHD1L-shRNA2), and Adv-Lacz was
included as a negative control. To test the efficiency of inhibition
by CHD1L-shRNAs on the expression of CHD1L in PLC8024
cells, cells were infected with various concentrations of virus
ranging from a multiplicity of infection (MOI) of 1.5 to 50. Real-
time quantitative PCR and western blot analyses showed that
CHD1L-shRNAs could efficiently silence CHD1L expression at
both the mRNA and protein levels (figure 5A,B). In vitro assays
were then used to investigate the inhibitory effects of CHD1L-
shRNAs on tumorigenicity in the HCC cell line PLC8024.
Compared with Adv-Lacz-infected cells, CHD1L-shRNA-
infected cells showed a lower efficiency of foci formation
(p<0.01, independent Student t test, figure 5C). Similarly, the
colony formation in soft agar was significantly reduced in
CHD1L-shRNA-infected cells compared with Adv-Lacz-infected
cells (p<0.001, independent Student t test, figure 5D). Next,
XTT proliferation assays showed that after viral infection,
the growth rate of PLC8024 cells was significantly inhibited
by CHD1L-shRNAs (p<0.001, independent Student t test;
figure 5E). Importantly, after viral infection followed by treat-
ment with 5-FU at different concentrations (0, 10, 25, 50, 100
and 150 mg/ml; IC50 at 75 mg/ml) for 72 h, the cell viability was
significantly inhibited by CHD1L-shRNA-treated cells when
compared with Adv-Lacz-infected cells (p<0.05, independent
Student t test; figure 5F).
Virus-mediated CHD1L silencing inhibits tumorigenesis and
increases chemosensitivity to 5-FU in nude mice
To explore the effect of CHD1L-shRNA in vivo, xenograft
tumours were generated by injecting PLC8024 cells subcutane-
ously into nude mice. When the xenograft tumours reached
w5 mm3, each group of mice (5 mice per group) was given
CHD1L-shRNA1 or Adv-Lacz (intratumoral injection, 23109
plaque-forming units (pfu), once a week for 6 weeks), combined
Figure 6 CHD1L depletion by
adenoviral CHD1L-shRNAs (short haipin
RNAs) inhibits tumorigenicity and
increases the chemosensitivity to
5-fluorouracil (5-FU) in vivo.
(A) Representative images of xenograft
tumours in nude mice induced by
PLC8024 cells. Left column, before
treatment; middle column, 6 weeks
after treatment with adenoviral vectors
(intratumoral injection, 23109 plaque-
forming units, once a week for 6 weeks)
combined with 5-FU (intraperitoneal
injection, 40 mg/kg body weight, once
a week for 6 weeks) or phosphate-
buffered saline (PBS); right column.
representative of tumours excised from
mice after 6 weeks of treatment.
(B) The tumour growth curve of each
group of mice which received the
scheduled treatment as described above
(n¼5, **p<0.0001). (CeE)
Immunohistochemical staining of CHD1L
(C) and proliferating cell nuclear antigen
(PCNA) (D) and TUNEL
(deoxyribonucleotidyl transferase
(TDT)-mediated dUTP-digoxigenin nick
end labelling) assay (E) were performed
on serial sections of xenograft tumours
excised from mice after 6 weeks of
treatment. Arrows indicate the strong
nuclear expression of PCNA (D) and
TUNEL-positive cells (E).
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with 5-FU (intraperitoneal injection, 40 mg/kg body weight,
once a week for 6 weeks) or PBS. Compared with the Adv-Lacz/
PBS group, tumour growth rates and tumour volumes were
significantly inhibited in the three other groups (figure 6A,B).
Upon intraperitoneal treatment with PBS, the average tumour
volume of the harvested xenograft tumours from the CHD1L-
shRNA1 group (55612 mm3) was significantly smaller than
tumours from the Adv-Lacz group (320665 mm3, p<0.0001,
independent Student t test). Interestingly, the inhibitory effect
of CHD1L-shRNA1 on tumour growth was similar to that of
5-FU treatment (figure 6B). Furthermore, when mice were
treated with the combination of CHD1L-shRNA1 and 5-FU, the
tumour growth was significantly inhibited compared with
mice treated with either CHD1L-shRNA1 or 5-FU (p<0.0001;
independent Student t test, figure 6B). In 3/5 of mice treated
with CHD1L-shRNA1 and 5-FU, the tumour had completely
disappeared after 6 weeks.
To investigate further the effect of CHD1L-shRNA1 on the
chemosensitivity to 5-FU in vivo, immunohistochemical
staining of proliferating cell nuclear antigen (PCNA) and
CHD1L, as well as TUNEL assay were performed to detect the
proliferating and apoptotic cells on serial sections of xenograft
tumours from 5-FU-injected mice. The results showed that the
endogenous expression of CHD1L was apparently decreased in
CHD1L-shRNA1-treated tumours compared with Adv-Lacz-
injected tumours (figure 6C). As expected, fewer PCNA-positive
(figure 6D) and more TUNEL-positive cells (figure 6E) were
observed in tumours treated with CHD1L-shRNA1, compared
with Adv-Lacz-treated tumours. All these data suggested that
silencing endogenous CHD1L expression by virus-mediated
RNA interference (RNAi) might inhibit the tumorigenicity and
increase the chemosensitivity to 5-FU.
DISCUSSION
HCC is a major health problem worldwide because of
its extremely poor prognosis. The high mortality rate for HCC
is due to the limited treatment options. Potential curative
treatments including liver resection, transplantation and percu-
taneous ablation are available for early-stage HCC, which
accounts for 30e40% of all HCC cases.16e18 TACE is the
recommended first-line non-curative treatment for patients with
large multifocal inoperable HCC19 because it has been shown to
have survival benefits in recent randomised controlled trials.20 21
Although chemotherapy can improve the survival rate for
advanced HCC cases, chemoresistance remains a tremendous
therapeutic challenge in treating HCC.16 22 23 The efficacy of
chemotherapeutic drugs is generally believed to depend on their
ability to trigger apoptosis.4 5 Therefore, identification and
characterisation of genes correlated with chemoresistance is
imperative to understand the molecular mechanism of chemo-
resistance in HCC and find new therapeutic targets for HCC
treatment.
Amplification of 1q21 is an early event in HCC develop-
ment,24 implying that the putative oncogene within this region
may play an important role in the initiation of HCC patho-
genesis. In our previous studies, we isolated a candidate onco-
gene CHD1L10 and demonstrated that its oncogenic function is
associated with its antiapoptotic role.12 In the present study,
HCC tissues showed increased expression of CHD1L compared
with non-tumour (including cirrhotic) tissues in all 109 cases
examined. Overexpression of CHD1L was significantly associ-
ated with tumour microsatellite formation, advanced tumour
stage and shorter OS time. In addition, overexpression of
CHD1L was also significantly associated with poor response to
chemotherapy in 50 patients with HCC who received the TACE
treatment with 5-FU in combination with DOX and CDDP. As
reported previously, CHD1L could confer strong resistance to
apoptosis by inhibiting Nur77-mediated apoptosis.12 These
findings provide us with new insights into the clinical value of
CHD1L and its role in drug resistance in HCC. The role
of CHD1L as an indicator and target in chemosensitivity was
further investigated in this study. The results showed
that CHD1L could confer drug resistance against chemothera-
peutic agents, such as 5-FU, that induce apoptosis through the
Nur77-mediated pathway. However, CHD1L fails to confer
chemoresistance to agents such as DOX, that induce apoptosis
through other pathways. Interestingly, it has been reported that
the administration of 5-FU does not significantly benefit
patients with HCC,25 and a clinical study indicated that
patients with HCC treated with 5-FU had a lower 2-year
survival rate than patients treated with DOX.14 Taken together,
these data demonstrate that the overexpression of CHD1L is one
of the major mechanisms of chemoresistance to 5-FU in HCC
treatment.
Given that CHD1L is frequently overexpressed in HCC,
CHD1L may become a useful new therapeutic target in HCC
treatment. DNA vector-based shRNA as a means of RNAi is
a promising mechanism for the precise disruption of gene
expression to achieve a therapeutic effect. However, the clinical
usage of shRNA therapeutics in cancer is limited by ineffective
delivery into target cancer cells. The viral delivery of shRNAs
has been reported to be used for tumour-specific gene therapy to
reverse the oncogenic phenotype of cancer cells.26 Adenoviral
vectors can efficiently transduce genes into a broad range of cell
types and have been used extensively as gene delivery vehicles.27
In recent years, adenoviral vectors carrying shRNA expression
cassettes have been developed and tested in several studies.28e30
In this study, we generated Adv-CHD1L-shRNAs and tested the
therapeutic efficacy of this viral construct in a HCC cell line
PLC8024 in vitro and in vivo. We found that this viral construct
could significantly inhibit the endogenous expression of CHD1L
in vitro. Further studies indicated that Adv-CHD1L-shRNAs
were able to suppress cell growth, clonogenicity and chemo-
resistance to 5-FU in vitro. More interestingly, in vivo studies
showed that Adv-CHD1L-shRNAs could inhibit xenograft
tumour growth and increase the sensitivity to 5-FU. The
inhibitory efficiency of CHD1L-shRNA is similar to 5-FU treat-
ment. The combination of CHD1L-shRNA and 5-FU showed
a significant inhibitory effect on tumour growth in nude mouse
compared with the treatment with either CHD1L-shRNA or
5-FU alone. In addition, complete tumour disappearance was
observed in 3/5 tested mice. These data strongly suggest that
silencing CHD1L expression in HCC by the corresponding
shRNA has a great therapeutic potential in HCC treatment,
especially to increase the chemosensitivity combined with
chemotherapy.
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